OPKO Health vs Telix Pharmaceuticals
OPK and TLX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How OPK and TLX compare
Telix Pharmaceuticals grew revenue faster over the last twelve months (55.6% versus −8.3% for OPKO Health).
Telix Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −0.89% compared with −29.5% at OPKO Health.
OPKO Health scores higher on the StockData Score (8 against 3 for Telix Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | OPK | TLX |
|---|---|---|
| Size and price | ||
| Market cap | $1.3B | – |
| Share price | $1.68 | $9.23 |
| Change, 1 year | 27.3% | −5.9% |
| Change, 5 years | −61.4% | – |
| Beta (5Y) | 0.92 | 1.45 |
| Employees | 2,275 | 1,120 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 2 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 2 (better) | 1 |
| Health score | 3 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.5× | – |
| P/B | 1.1× | – |
| FCF yield | −10.8% | – |
| Fair value | $2.10 | – |
| Margin of safety | 20.0% | – |
| Growth | ||
| Revenue growth (TTM) | −8.3% | 55.6% (better) |
| Revenue growth, 5Y average | −15.8% | – |
| Net income growth (TTM) | – | −121% |
| EPS growth (TTM) | – | −122% |
| Profitability | ||
| Gross margin | 56.6% (better) | 53.1% |
| Operating margin | −17.5% | 3.7% (better) |
| Net margin | −29.5% | −0.89% (better) |
| FCF margin | −27.0% | −5.3% (better) |
| Return on equity | −12.2% | – |
| Return on invested capital | −8.5% | – |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Net debt / EBITDA | – | 5.17 |
| Interest coverage | – | 0.7× |
| Current ratio | 4.97 (better) | 2.01 |
| Altman Z-score | −0.28 | – |
| Piotroski F-score | 4 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | 3.3% | – |
| Shareholder yield | 3.3% | – |
| Ownership | ||
| Held by institutions | 27.2% | 0.94% |
| Held by insiders | 43.6% | 8.3% |
| Insider net buying, 12 months | −$13.2K | $1.0M (better) |
| Short interest, % of float | 7.8% | – |
Go deeper
- OPK stock overview
- OPK income statement
- OPK valuation and score
- TLX stock overview
- TLX income statement
- TLX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.